Viral evolution and escape during primary human immunodeficiency virus-1 infection: implications for vaccine design

被引:7
作者
Mullins, James I. [2 ,3 ]
Rolland, Morgane [2 ,3 ]
Allen, Todd M. [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Partners AIDS Res Ctr, Boston, MA USA
[2] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
evolution; HIV; T lymphocyte; viral proteins;
D O I
10.1097/COH.0b013e3282f233d9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of review The ability of human immunodeficiency virus to mutate rapidly to evade host immune pressures is a key hurdle limiting the control of human immunodeficiency virus-1 by cellular immune responses. Viral escape from CD8(+) T-cell recognition continues to be studied extensively, and emerging data provide greater appreciation of the affect of these mutations on the virus. These data may help identify key immune responses capable of suppressing viral replication. This goal remains critical, as current vaccines are unlikely to produce protective T-cell immunity. Recent findings Recent studies provide greater understanding of the propensity for transmitted mutations to revert, and of the ability of CD8(+) T-cell escape mutations to impact viral replication capacity and protein structure. These observations reveal important constraints on virus evolution and sequence diversity. Data are also accumulating for the ability of the immune system to mount de-novo CD8(+) T-cell responses against escape variants, revealing an underappreciated complexity of the process of viral escape. Summary Understanding the limits of sequence variation and the impact of immune escape mutations on viral fitness, particularly during acute infection, will be critical to guide the design of contemporary vaccines or therapeutics attempting to force human immunodeficiency viruses to become less fit.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 50 条
[21]   MULTIPLE SUPERINFECTIONS FAIL TO ACTIVATE DEFECTIVE HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1) INFECTION OF RABBITS [J].
SELL, S ;
TSENG, CK .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 9 (03) :211-226
[22]   Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection [J].
Samaras, Katherine .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) :238-245
[23]   Pharmacological advances in anti-retroviral therapy for human immunodeficiency virus-1 infection: A comprehensive review [J].
Azzman, Nursyuhada ;
Gill, Muhammad Shoaib Ali ;
Hassan, Sharifah Syed ;
Christ, Frauke ;
Debyser, Zeger ;
Mohamed, Wan Ahmad Syazani ;
Ahemad, Nafees .
REVIEWS IN MEDICAL VIROLOGY, 2024, 34 (02)
[24]   The interaction of human immunodeficiency virus-1 and human endogenous retroviruses in patients (primary cell cultures) and cell line models [J].
Mantovani, Federica ;
Kitsou, Konstantina ;
Paraskevis, Dimitrios ;
Lagiou, Pagona ;
Magiorkinis, Gkikas .
MICROBIOLOGY SPECTRUM, 2023, 11 (06)
[25]   Severe Thrombocytopenia and Acute Cytomegalovirus Colitis during Primary Human Immunodeficiency Virus Infection [J].
Furuhata, Masanori ;
Yanagisawa, Naoki ;
Nishiki, Shingo ;
Sasaki, Shugo ;
Suganuma, Akihiko ;
Imamura, Akifumi ;
Ajisawa, Atsushi .
INTERNAL MEDICINE, 2016, 55 (24) :3671-3674
[26]   Tenidap inhibits replication of the human immunodeficiency virus-1 in cultured cells [J].
Dezube, BJ ;
Ahlers, CM ;
Lawrence, JP ;
Teng, EI ;
Silberman, SL ;
Pardee, AB ;
Finberg, RW .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1997, 14 (01) :13-17
[27]   Human immunodeficiency virus-1 genome from patient with fever, Nepal [J].
Tuladhar, Eans Tara ;
Chalise, Bimal Sharma ;
Khadka, Binod ;
Tamang, Mamta ;
Neupane, Jenish ;
Poudel, Shankar ;
Droit, Lindsay ;
Mihindukulasuriya, Kathie A. ;
Ngono, Annie Elong ;
Basaula, Yuba Nidhi ;
Shresta, Sujan ;
Wang, David ;
Manandhar, Krishna Das .
MICROBIOLOGY RESOURCE ANNOUNCEMENTS, 2024, 13 (11)
[28]   Glycosylation of Simian Immunodeficiency Virus Influences Immune-Tissue Targeting during Primary Infection, Leading to Immunodeficiency or Viral Control [J].
Sugimoto, Chie ;
Nakamura, Shinichiro ;
Hagen, Shoko I. ;
Tsunetsugu-Yokota, Yasuko ;
Villinger, Francois ;
Ansari, Aftab A. ;
Suzuki, Yasuo ;
Yamamoto, Naoki ;
Nagai, Yoshiyuki ;
Picker, Louis J. ;
Mori, Kazuyasu .
JOURNAL OF VIROLOGY, 2012, 86 (17) :9323-9336
[29]   Human immunodeficiency virus-1 core: The Trojan horse in virus-host interaction [J].
Wang, Wei ;
Li, Yan ;
Zhang, Zhe ;
Wei, Wei .
FRONTIERS IN MICROBIOLOGY, 2022, 13
[30]   Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment [J].
Piccolo, P ;
Borg, L ;
Lin, A ;
Melia, D ;
Ho, A ;
Kreek, MJ .
JOURNAL OF ADDICTIVE DISEASES, 2002, 21 (04) :55-66